For example, when prehypertensive men and women (mean age 49 years) were randomized to receive an angiotensin II receptor antagonist (ARB) or placebo for 2 years, hypertension developed in 40% of the placebo recipients, and only 14% of the active drug recipients (66% PR-171 in vivo relative risk reduction). When the active drug was discontinued and participants were followed

for an additional 2 years, those who originally received ARB maintained significantly lower systolic (−2 mmHg) and diastolic (−1.1 mmHg) blood pressures, and maintained their lower relative risk for developing hypertension (15%) than the placebo recipients. This suggests that even small decrements in systolic and diastolic blood pressure that can be maintained for prolonged periods can postpone the progression of hypertension. In another cohort study [46], normotensive men and women (<120/80 mmHg) with modest coronary artery disease who controlled their blood pressures using either an angiotensin-converting enzyme inhibitor or a calcium-channel blocker had the largest decrease in coronary atheroma volume (using intravascular ultrasound) after 2 years, while participants with baseline pre-hypertension or hypertension had no significant reduction or an increase in atheroma volume. This suggests that early anti-hypertensive

interventions, even in people with normal blood pressures, effectively reduce the progression of atherogenesis. In HIV-infected people with pre-hypertension and other cardiometabolic risk factors (e.g. tobacco use, Proteases inhibitor central adiposity and dyslipidaemia) it seems prudent to recommend lifestyle modifications (including yoga) to reduce blood pressures. Randomized trials and observational studies are consistent in that a 10 mmHg reduction in systolic blood pressure and a 5 mmHg reduction in diastolic blood pressure predict ∼50–60% lower risk for death from stroke,

and ∼40–50% lower risk for death from coronary artery (or other vascular) disease [40,42]. In the current study, average reductions in systolic/diastolic blood pressures were 5/3 mmHg. Assuming that HIV-infected people respond similarly to the general population, our findings suggest that the risk of death from stroke was reduced by 25–30% and the risk of death from coronary artery disease was reduced by 20–25% by this yoga intervention. 17-DMAG (Alvespimycin) HCl Yoga was selected as the intervention because complementary and alternative medicine advocates believe that yoga’s approach to synchronizing breath inhalation, exhalation or held breath to movement in conjunction with focusing the mind on a specific region of the body optimizes the interaction between the autonomic nervous system and endocrine system [16,47,48]. We hypothesized that yoga would reduce body fat because energy expenditure during Hatha/Ashtanga yoga averaged 2.5 METS (3 kcal/min) and peak energy expenditure was 11 METS (14 kcal/min) [49,50]; however, fat loss was not observed.